chufangao/CTO huggingface dataset:
Clinical trial NCT02609828: Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy
Official title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAIN PREDOMINANTLY DUE TO BONE METASTASIS RECEIVING BACKGROUND OPIOID THERAPY
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 156.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-10-28
Primary completion date: 2020-09-17
Completion date: 2021-06-25
Baseline population: The safety analysis set included all participants treated with tanezumab or placebo SC, including participants who received tanezumab 10 mg prior to protocol amendment 3.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT01897714: Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
Official title: An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients With Relapsed and/or Relapsed-Refractory Multiple Myeloma
Sponsor: Oncopeptides AB (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The study was terminated at median 46-48 months long term follow-up and mature overall survival follow-up data.
Enrollment: 75.0 (ACTUAL)
Number of arms: 6.0
Start date: 2013-07-31
Primary completion date: 2017-12-31
Completion date: 2020-03-31
Baseline population: The Safety Analysis Set included all patients who received at least 1 dose, or part thereof, of study drug.
Limitations and caveats: Study is terminated and long-term follow-up ended due to Sponsor decision.
Clinical trial NCT04516603: Influence of Fampridine on Working Memory in Healthy Subjects
Official title: Randomized Placebo-controlled Phase II Cross-over Study on the Influence of Fampridine on Working Memory in Healthy Subjects
Acronym: Fampyr_2020
Sponsor: University of Basel (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Changement of study design. Restart spring 2021.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-01
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Plan to share individual participant data: YES
IPD sharing description: All IPD (de-identified) that underlie results in a publication will be shared upon reasonable request.
IPD time frame: IPD will be available after publication, study protocol (including statistical analysis plan) will be made available before start of the study.
IPD access criteria: All IPD (de-identified) that underlie results in a publication will be shared upon reasonable request for scientific purposes. A reasonable request consists of a short description of the scientific purpose. Requests will be reviewed by the team of the principle investigator.
Clinical trial NCT04607980: A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Official title: A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared With Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 563.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-11
Primary completion date: 2022-01-13
Completion date: 2022-06-03
Baseline population: Full Analysis Set (FAS): consisted of all randomized participants.
Limitations and caveats: Due to non-convergence of the generalized linear model used for pre-specified analyses, ad hoc analyses were conducted for efficacy endpoints of PASI 75 response, PASI 100 response, and sPGA response.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Clinical trial NCT02908451: A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
Official title: A Phase I Dose Escalation Study, With Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients With Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, Pancreatic or Biliary Cancer
Sponsor: AbGenomics B.V Taiwan Branch (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: COVID-19 pandemic has caused a huge operational difficulty for this ongoing clinical trial, as many hospitals have set limitations on onsite staff, patient visits, study related procedures and onsite monitoring visits.
Enrollment: 39.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-04-24
Primary completion date: 2021-02-28
Completion date: 2021-02-28
Plan to share individual participant data: NO
Clinical trial NCT03529331: A Study Comparing Recurrent Use of MSIR, Percocet, and Vicodin at Discharge From the ED
Official title: A Study Comparing Recurrent Use of Morphine Sulfate Immediate Release, Oxycodone/Acetaminophen (Percocet), and Hydrocodone/Acetaminophen (Vicodin) at Discharge From the ED in Opioid-naïve Adult Patients With Moderate to Severe Pain.
Sponsor: Maimonides Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: The ED physicians no longer prescribe opioids at discharge; not feasible to conduct the study
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-09-01
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT02477839: Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures
Official title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy >=1 Month to <4 Years of Age With Partial-Onset Seizures
Sponsor: UCB Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 255.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-06-05
Primary completion date: 2020-05-28
Completion date: 2020-05-28
Baseline population: Baseline Characteristics refer to the Safety Set (SS) which consisted of all randomized study participants who took at least 1 dose of study medication.
Clinical trial NCT03773562: Imaging the Migraine Brain Pre- and Post-Erenumab
Official title: Imaging the Migraine Brain Pre- and Post-Erenumab: an MRI Study to Identify Functional and Structural Changes That Correlate With Patient Improvement
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-25
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Plan to share individual participant data: NO
Clinical trial NCT05250856: CNP-201 in Subjects With Peanut Allergy
Official title: A Phase 1b/2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of CNP-201 in Subjects Ages 16-55 With Peanut Allergy
Sponsor: COUR Pharmaceutical Development Company, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lagging Enrollment and Administrative Reasons
Enrollment: 15.0 (ACTUAL)
Number of arms: 5.0
Start date: 2022-03-14
Primary completion date: 2023-12-12
Completion date: 2023-12-12
Plan to share individual participant data: NO
Clinical trial NCT02856698: MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial)
Official title: Study Design and Rationale of A Multicenter, Open-Labeled, Randomized Controlled Trial Comparing MIdazolam Versus MOrphine in Acute Pulmonary Edema: MIMO Trial
Acronym: MIMO
Sponsor: Hospital Universitario de Canarias (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The study was stopped because of the adverse events
Enrollment: 111.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-04-08
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Baseline population: All quantitative and categorical variables were expressed as median (interquartile range) and n (%) and were compared using the Mann-Whitney U test and Fisher's exact test respectively.
Limitations and caveats: The main limitation of the study was that the study treatment, because it was a serious pathology, was sometimes administered in the ambulance, before admission to the hospital emergency room.~Another limitation has been the COVID-19 pandemic
Plan to share individual participant data: NO
Clinical trial NCT04208997: Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation
Official title: Continuation of Antiarrhythmics Following caThEteR Ablation for Ventricular Tachycardia (AFTER-VT) Trial: A Pilot Randomized Clinical Trial
Acronym: AFTER-VT
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study was terminated due to low accrual
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-19
Primary completion date: 2021-06-30
Completion date: 2021-06-30
Plan to share individual participant data: NO
Clinical trial NCT04573218: Supplementation of Oil Palm Phenolics to Improve Lipid Profile in Subjects With Minor Hyperlipidaemia
Official title: Supplementation of Oil Palm Phenolics to Improve Lipid Profile in Subjects With Minor Hyperlipidaemia (Phase 2 Clinical Trial Study)
Sponsor: National University of Malaysia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-18
Primary completion date: 2021-12-16
Completion date: 2021-12-20
Plan to share individual participant data: NO
Clinical trial NCT04773600: Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)
Official title: A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects With Atopic Dermatitis
Sponsor: Arcutis Biotherapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 683.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-24
Primary completion date: 2022-09-29
Completion date: 2022-09-29
Clinical trial NCT05254808: EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care
Official title: EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care
Acronym: EXFOCY
Sponsor: UMC Utrecht (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Insufficient participating sites, and insufficient participants from participating sites mainly due to COVID-19 workload. The number of necessary participants could not be reached within the anticipated timelines and the allocated budget.
Enrollment: 13.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-09-06
Primary completion date: 2022-02-14
Completion date: 2022-02-14
Plan to share individual participant data: NO
Clinical trial NCT03275792: Shiga Toxin Producing Escherichia Coli (STEC) Volume Expansion
Official title: Inpatient Volume Expansion in Children With Shiga Toxin-Producing Escherichia Coli (STEC) Infection to Prevent Hemolytic Uremic Syndrome (HUS)
Sponsor: University of Calgary (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Funding not obtained.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-31
Primary completion date: 2021-04-30
Completion date: 2021-04-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03449147: A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN030)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1317.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-03-15
Primary completion date: 2020-08-20
Completion date: 2020-10-30
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT03532958: Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of Intravenous BNZ-1 in Patients With Moderate to Severe Alopecia Areata
Sponsor: Equillium (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Transfer of study sponsor
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-10-31
Primary completion date: 2022-11-30
Completion date: 2022-11-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03990571: Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Official title: A Phase 2 Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma (ACC)
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-22
Primary completion date: 2023-03-20
Completion date: 2023-03-20
Baseline population: 40 participants enrolled from July 2019 to June 2021 (6 were screen failures), 34 were treated and 6 of the 34 were evaluable for safety only and did not undergo the first re-staging imaging assessment
Clinical trial NCT03208127: DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant
Official title: Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Liver Transplant
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Protocol transitioned to standard of care, no funding available to continue support of research work or data analysis
Enrollment: 33.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-11-21
Primary completion date: 2021-06-04
Completion date: 2021-06-04
Baseline population: Baseline Analysis population is number of consented subjects initiating Direct Antiviral Treatment
Limitations and caveats: Protocol transitioned out of research to standard of care and was closed prior to completion and planned enrollment goal was not met. Review of data from enrolled patient was used for reporting purposes and data is primarily descriptive and not based on statistical analysis.
Plan to share individual participant data: YES
IPD sharing description: Coded data is anticipated to be shared with potential collaborators.
IPD time frame: Anticipated that data from the study will become available within 6 months after the final patient completes the primary study endpoint (12 weeks post treatment)
IPD access criteria: Data would only be shared with Institutional Review Board (IRB) approved collaborators.
Clinical trial NCT03475680: Mechanical Bowel Preparation and Oral Antibiotics Before Colon Cancer Surgery
Official title: Mechanical Bowel Preparation and Oral Antibiotics Before Colon Cancer Surgery: a Multi Center Double-Blinded Randomized Controlled Trial (COLONPREP Study)
Acronym: COLONPREP
Sponsor: Assistance Publique - Hôpitaux de Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: lack of inclusions
Enrollment: 193.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-08-08
Primary completion date: 2021-08-26
Completion date: 2022-03-23
Plan to share individual participant data: NO
IPD sharing description: There is not a plan to make IPD available
Clinical trial NCT03835871: Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma
Official title: A Randomized, Parallel Group, Multicenter, Double -Blind, Double-dummy, Placebo-controlled Phase 3 Study With Beclomethasone Dipropionate HFA at 100 μg, 200 μg and 400 μg Daily Doses Compared to Placebo in Mild or Moderate Persistent Asthma
Sponsor: Adamis Pharmaceuticals Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Sponsor decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-02-28
Primary completion date: 2019-12-31
Completion date: 2020-05-31
Clinical trial NCT03973333: Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
Official title: A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer
Sponsor: Immunocore Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The Sponsor terminated the study and there is no further enrollment. Endpoints will not be assessed for this trial.
Enrollment: 75.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-05-17
Primary completion date: 2023-09-25
Completion date: 2023-09-25
Clinical trial NCT03602339: Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose
Official title: LowEr Administered Dose With highEr Relaxivity: Gadovist vs Dotarem (LEADER 75)
Acronym: LEADER 75
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 157.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-14
Primary completion date: 2020-03-13
Completion date: 2020-05-26
Clinical trial NCT04232449: Oral Corticosteroids for Post-infectious Cough in Adults
Official title: Oral Corticosteroids for Post-infectious Cough in Adults: A Double-blind Randomised Placebo-controlled Trial in Swiss Family Practices (OSPIC Trial)
Acronym: OSPIC
Sponsor: University Hospital, Basel, Switzerland (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: too few patients were included
Enrollment: 32.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-06
Primary completion date: 2024-04-30
Completion date: 2024-04-30
Clinical trial NCT04252417: HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects
Official title: Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Single Oral Administration of MD1003 100 mg in Hepatic Impaired Patients and Healthy Subjects With Normal Hepatic Function
Sponsor: MedDay Pharmaceuticals SA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to other Phase 3 trial failure to meet primary endpoint
Enrollment: 15.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-11
Primary completion date: 2020-03-17
Completion date: 2020-03-17
Clinical trial NCT05085574: Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)
Official title: A Phase 2 Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Combination of Famotidine and Celecoxib as a Treatment in Moderate-to-severe Patients Hospitalized for COVID-19
Sponsor: Leidos Life Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: COVID environment, lack of site confidence to enroll subjects, sites not suited to study procedures, decline of potential inpatient subjects at site
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-02-07
Primary completion date: 2023-02-07
Completion date: 2023-02-07
Plan to share individual participant data: UNDECIDED
IPD sharing description: It is not yet known if there will be a plan to make individual participant data (IPD) available.
Clinical trial NCT02000934: A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies
Official title: An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies
Sponsor: Calithera Biosciences, Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 143.0 (ACTUAL)
Number of arms: 9.0
Start date: 2013-12-31
Primary completion date: 2021-06-29
Completion date: 2021-06-29
Plan to share individual participant data: YES
IPD sharing description: Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Clinical trial NCT05614453: Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy
Official title: A Phase II Trial of Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy
Acronym: ITTACC
Sponsor: Australia New Zealand Gynaecological Oncology Group (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: BeiGene has withdrawn their support owing to sitravatinib supply concerns. Mirati is ceasing further development of sitravatinib owing to the negative results of the SAPPHIRE trial which used sitravatinib in 2nd line met NSCLC setting.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-06-30
Primary completion date: 2023-06-30
Completion date: 2023-06-28
Plan to share individual participant data: NO